Trials / Terminated
TerminatedNCT00076206
Study Evaluating CCI-779 in Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy
A Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate the Efficacy and Safety of 3 Different Oral Dose Levels (1, 2, And 4 Mg) of CCI-779 in Subjects With Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to compare the therapeutic response and safety of 3 oral dose levels of CCI-779, with placebo in subjects with active rheumatoid arthritis (RA) who have been receiving stable doses of methotrexate (MTX) for at least 8 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CCI-779 | |
| DRUG | Placebo |
Timeline
- Start date
- 2003-12-01
- Primary completion
- 2005-08-01
- Completion
- 2005-08-01
- First posted
- 2004-01-19
- Last updated
- 2015-12-09
Source: ClinicalTrials.gov record NCT00076206. Inclusion in this directory is not an endorsement.